Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Moffitt Cancer Center Researchers Develop and Test New Anti-Cancer Vaccine

11.06.2012
Synthetic vaccine effective in killing HPV-caused tumors in mice
Researchers at Moffitt Cancer Center have developed and tested in mice a synthetic vaccine and found it effective in killing human papillomavirus-derived cancer, a virus linked to cervical cancers among others. The research was published in a recent issue of Cancer Immunology, Immunotherapy.

"Vaccines for cancer can be good alternatives to conventional therapies that result in serious side-effects and are rarely effective against advanced disease," said Esteban Celis, M.D., Ph.D., senior member and professor in Moffitt's Immunology Program. "The human papillomavirus, or HPV, is known to cause 99 percent of cervical cancers and annually causes more than 250,000 deaths worldwide." In addition, HPV is the causative agent of a large proportion of head and neck and genital cancers.

Although two approved prophylactic vaccines against strains of HPV that cause cervical cancer are now in wide use as a measure to prevent HPV infections, these vaccines cannot be used to treat HPV-induced cancers. Thus, there is a need to develop therapeutic vaccines for HPV-related tumors.

In an effort to find an effective HPV-cancer vaccine that would eliminate existing HPV-induced cancer, Celis and Kelly Barrios-Marrugo, Ph.D., of the University of South Florida College of Medicine's Molecular Medicine program, designed a peptide vaccination strategy called TriVax-HPV.

The TriVax vaccine strategy was designed to generate large numbers of cytotoxic T-cells that would seek out the proteins preferentially expressed in the tumors. The HPV16-E6 and E7 proteins function as oncogenic proteins inducing cancer. Thus, according to Celis and Barrios-Marrugo, a vaccine targeting these viral proteins is an "ideal candidate" to create strong immune responses, with the additional benefit of not generating autoimmune-related pathologies.

When they tested their vaccine in mice with HPV16-induced tumors, they found that TriVax containing a small synthetic fragment (peptide) of the E7 protein "induced tumor clearance in 100 percent of the treated mice" while the unvaccinated mice with HPV-induced tumors had their tumors grow "at a fast rate."

"Although the magnitude of the T-cell responses achieved with TriVax in mice is impressive," Barrios-Marrugo said," we do not know whether similar effects can be accomplished in humans."

Celis and Barrios-Marrugo point out that current therapies for cervical cancer can be devastating, highly toxic and associated with a 10 percent chance of recurrence. Additionally, a significant proportion of women in the Third World will not receive the approved prophylactic vaccine to prevent HPV infection and, thus, will continue at high risk for cervical and other cancers related to HPV.

"We believe that these studies may help to launch more effective and less invasive therapeutic vaccines for HPV-caused malignancies," concluded the authors.

Their research was supported by National Institutes of Health grants RO1CA136828 and RO1CA157303.

About Moffitt Cancer Center
Follow Moffitt on Facebook: www.facebook.com/MoffittCancerCenter
Follow Moffitt on Twitter: @MoffittNews
Follow Moffitt on YouTube: MoffittNews

Located in Tampa, Moffitt Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center, which recognizes Moffitt's excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt is also a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer.

Media release by Florida Science Communications

Patty Kim | EurekAlert!
Further information:
http://www.moffitt.org

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>